Prelude Therapeutics

(NASDAQ) PRLD

Current Price$4.51

Market Cap$282.25M

Since IPO (2020)-83%

5 Year-89%

1 Year+378%

1 Month-19%

Prelude Therapeutics Financials at a Glance

Market Cap

$282.25M

Revenue (TTM)

$16.72M

Net Income (TTM)

$77.80M

EPS (TTM)

$-1.06

P/E Ratio

-4.24

Dividend

$0.00

Beta (Volatility)

1.57 (High)

Dividend

$0.00

Beta (Volatility)

1.57 (High)

Price

$4.51

Volume

12,807

Open

$4.38

Price

$4.51

Volume

12,807

Open

$4.38

Previous Close

$4.48

Daily Range

$4.30 - $4.75

52-Week Range

$0.75 - $5.54

Dividend

$0.00

Beta (Volatility)

1.57 (High)

Price

$4.51

Volume

12,807

Open

$4.38

Previous Close

$4.48

Daily Range

$4.30 - $4.75

52-Week Range

$0.75 - $5.54

PRLD News

Prelude Cuts Q2 Losses and Costs 13%

Motley Fool Markets TeamAug 14, 2025

PRLD: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Prelude Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Krishna Vaddi, PhD

Website

www.preludetx.com

Headquarters

Wilmington, DE 19803, US

PRLD Financials

Key Financial Metrics (TTM)

Gross Margin

98%

Operating Margin

-5%

Net Income Margin

-5%

Return on Equity

-95%

Return on Capital

-1%

Return on Assets

-65%

Earnings Yield

-23.58%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$282.25M

Shares Outstanding

63.00M

Volume

12.81K

Avg. Volume

392.81K

Financials (TTM)

Gross Profit

$10.43M

Operating Income

$104.57M

EBITDA

$102.86M

Operating Cash Flow

$56.30M

Capital Expenditure

$67.00K

Free Cash Flow

$56.37M

Cash & ST Invst.

$103.21M

Total Debt

$17.79M

Prelude Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$4.58M

N/A

Gross Profit

$4.19M

N/A

Gross Margin

91.46%

N/A

Market Cap

$282.25M

N/A

Market Cap/Employee

$2.15M

N/A

Employees

131

N/A

Net Income

$10.38M

+67.6%

EBITDA

$13.79M

+59.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$63.83M

-21.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$14.96M

-2.0%

Short Term Debt

$2.76M

+4.1%

Return on Assets

-65.03%

N/A

Return on Invested Capital

-1.08%

N/A

Free Cash Flow

$21.68M

+36.7%

Operating Cash Flow

$21.68M

+36.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IVAInventiva S.A.

IVAInventiva S.A.$5.16-5.06%

ENTAEnanta Pharmaceuticals, Inc.

ENTAEnanta Pharmaceuticals, Inc.$13.67+1.95%

EPRXEupraxia Pharmaceuticals Inc.

EPRXEupraxia Pharmaceuticals Inc.$7.10+2.63%

OBIOOrchestra BioMed Holdings, Inc.

OBIOOrchestra BioMed Holdings, Inc.$3.81+2.42%

FHTXFoghorn Therapeutics Inc.

FHTXFoghorn Therapeutics Inc.$3.85+1.45%

CRBUCaribou Biosciences, Inc.

CRBUCaribou Biosciences, Inc.$2.08-2.69%

AVTXAvalo Therapeutics, Inc.

AVTXAvalo Therapeutics, Inc.$16.21-8.62%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.24-0.05%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$73.97-0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.75+0.02%

AIIORobo.ai

AIIORobo.ai$5.27+0.31%

IRENIren

IRENIren$49.66-0.06%

CISSC3is

CISSC3is$5.10+0.67%

TET1 Energy Inc.

TET1 Energy Inc.$6.64+0.17%

Questions About PRLD

What is the current price of Prelude Therapeutics?

Prelude Therapeutics is trading at $4.51 per share.

What is the 52-week range for Prelude Therapeutics?

Over the past 52 weeks, Prelude Therapeutics has traded between $0.75 and $5.54.

How much debt does Prelude Therapeutics have?

As of the most recent reporting period, Prelude Therapeutics reported total debt of $17.72M.

How much cash does Prelude Therapeutics have on hand?

Prelude Therapeutics reported $21.76M in cash and cash equivalents in its most recent financial results.

What is Prelude Therapeutics’s dividend yield?

Prelude Therapeutics does not currently have a dividend yield.

Prelude Therapeutics

Prelude Therapeutics Financials at a Glance

PRLD News

Prelude Cuts Q2 Losses and Costs 13%

PRLD: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Prelude Therapeutics

PRLD Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Prelude Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About PRLD

What is the current price of Prelude Therapeutics?

What is the 52-week range for Prelude Therapeutics?

How much debt does Prelude Therapeutics have?

How much cash does Prelude Therapeutics have on hand?

What is Prelude Therapeutics’s dividend yield?

Premium Investing Services